
Valeria Cernaro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9286538/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vascular access for hemodialysis: current perspectives. International Journal of Nephrology and Renovascular Disease, 2014, 7, 281.	1.8	209
2	Antioxidant agents for delaying diabetic kidney disease progression: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0178699.	2.5	87
3	Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials. Pharmacological Research, 2018, 129, 274-294.	7.1	47
4	Relaxin: New Pathophysiological Aspects and Pharmacological Perspectives for an Old Protein. Medicinal Research Reviews, 2014, 34, 77-105.	10.5	46
5	New Insights on the Role of Vitamin D in the Progression of Renal Damage. Kidney and Blood Pressure Research, 2013, 37, 667-678.	2.0	45
6	Beneficial effects of oral pure caffeine on oxidative stress. Journal of Clinical and Translational Endocrinology, 2017, 10, 22-27.	1.4	44
7	Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2017, 18, 2283.	4.1	41
8	Renal biopsy: Still a landmark for the nephrologist. World Journal of Nephrology, 2016, 5, 321.	2.0	37
9	Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease. Journal of Clinical and Translational Endocrinology, 2016, 6, 8-14.	1.4	34
10	Role of Vitamin D Status in Diabetic Patients with Renal Disease. Medicina (Lithuania), 2019, 55, 273.	2.0	34
11	Fibrosis, regeneration and cancer: what is the link?. Nephrology Dialysis Transplantation, 2012, 27, 21-27.	0.7	29
12	Metformin-related lactic acidosis: is it a myth or an underestimated reality?. Renal Failure, 2016, 38, 1560-1565.	2.1	29
13	Kidney-lung connections in acute and chronic diseases: current perspectives. Journal of Nephrology, 2016, 29, 341-348.	2.0	27
14	The relationship between coping, emotion regulation, and quality of life of patients on dialysis. International Journal of Psychiatry in Medicine, 2017, 52, 111-123.	1.8	27
15	Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. International Journal of Nephrology and Renovascular Disease, 2016, 9, 11.	1.8	25
16	Kidney disease and psoriasis: novel evidences beyond old concepts. Clinical Rheumatology, 2016, 35, 297-302.	2.2	25
17	Novel avenues for treating diabetic nephropathy: new investigational drugs. Expert Opinion on Investigational Drugs, 2017, 26, 445-462.	4.1	24
18	Erythropoiesis and chronic kidney disease–related anemia: From physiology to new therapeutic advancements. Medicinal Research Reviews, 2019, 39, 427-460.	10.5	24

VALERIA CERNARO

#	Article	IF	CITATIONS
19	Kidney Biopsy in Type 2 Diabetic Patients: Critical Reflections on Present Indications and Diagnostic Alternatives. International Journal of Molecular Sciences, 2021, 22, 5425.	4.1	24
20	Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease. International Journal of Endocrinology, 2015, 2015, 1-8.	1.5	22
21	Protective Role of Vitamin D in Renal Tubulopathies. Metabolites, 2020, 10, 115.	2.9	21
22	Apelin, Plasmatic Osmolality and Hypotension in Dialyzed Patients. Blood Purification, 2012, 33, 317-323.	1.8	20
23	New therapeutic strategies under development to halt the progression of renal failure. Expert Opinion on Investigational Drugs, 2014, 23, 693-709.	4.1	18
24	Vitamin D and Anemia. , 2014, 24, 61-62.		18
25	Delayed graft function and chronic allograft nephropathy: diagnostic and prognostic role of neutrophil gelatinase-associated lipocalin. Biomarkers, 2016, 21, 371-378.	1.9	18
26	Regenerative Medicine: Does Erythropoietin have a Role?. Current Pharmaceutical Design, 2009, 15, 2026-2036.	1.9	17
27	Sclerostin levels in uremic patients: a link between bone and vascular disease. Renal Failure, 2016, 38, 759-764.	2.1	17
28	Monoclonal antibodies for renal diseases: current concepts and ongoing treatments. Expert Opinion on Biological Therapy, 2015, 15, 1119-1143.	3.1	16
29	Monocyte to HDL ratio: a novel marker of resistant hypertension in CKD patients. International Urology and Nephrology, 2022, 54, 395-403.	1.4	16
30	NGAL is a Precocious Marker of Therapeutic Response. Current Pharmaceutical Design, 2011, 17, 844-849.	1.9	15
31	The future of phosphate binders: a perspective on novel therapeutics. Expert Opinion on Investigational Drugs, 2014, 23, 1459-1463.	4.1	15
32	NGAL as an Early Biomarker of Kidney Disease in Joubert Syndrome: Three Brothers Compared. Renal Failure, 2012, 34, 495-498.	2.1	14
33	RAS inhibition modulates kynurenine levels in a CKD population with and without type 2 diabetes mellitus. International Urology and Nephrology, 2020, 52, 1125-1133.	1.4	14
34	Down with the Erythropoietin. Long Live the Erythropoietin !. Current Drug Targets, 2009, 10, 1028-1032.	2.1	12
35	Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases. Pharmacological Research, 2020, 159, 105019.	7.1	11
36	Maternal and Fetal Outcomes of Pregnancy in Nephrotic Syndrome Due to Primary Glomerulonephritis. Frontiers in Medicine, 2020, 7, 563094.	2.6	10

#	Article	IF	Citations
37	Marked improvement of thyroid function and autoimmunity by Aloe barbadensis miller juice in patients with subclinical hypothyroidism. Journal of Clinical and Translational Endocrinology, 2018, 11, 18-25.	1.4	9
38	The Myth of Water and Salt: From Aquaretics to Tenapanor. , 2018, 28, 73-82.		8
39	Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology. Journal of Nephrology, 2020, 33, 417-430.	2.0	8
40	Erythropoietin and the truths of science. Journal of Nephrology, 2011, 24, 564-568.	2.0	8
41	Auxin induces cell proliferation in an experimental model of mammalian renal tubular epithelial cells. Renal Failure, 2015, 37, 911-913.	2.1	7
42	Nephro-oncology: a link in evolution. Renal Failure, 2015, 37, 1260-1266.	2.1	7
43	Iron Infusion and Induced Hypophosphatemia: The Role of Fibroblast Growth Factorâ€23. Therapeutic Apheresis and Dialysis, 2020, 24, 258-264.	0.9	7
44	Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease. Current Medicinal Chemistry, 2016, 23, 1698-1707.	2.4	7
45	Salt–water imbalance and fluid overload in hemodialysis patients: a pivotal role of corin. Clinical and Experimental Medicine, 2016, 16, 443-449.	3.6	6
46	Convective Dialysis Reduces Mortality Risk: Results From a Large Observational, Populationâ€Based Analysis. Therapeutic Apheresis and Dialysis, 2018, 22, 457-468.	0.9	6
47	Endothelial Progenitor Cells at the Interface of Chronic Kidney Disease: From Biology to Therapeutic Advancement. Current Medicinal Chemistry, 2018, 25, 4545-4551.	2.4	6
48	Renoprotective effect of erythropoietin in zebrafish after administration of gentamicin: an immunohistochemical study for l²-catenin and c-kit expression. Journal of Nephrology, 2017, 30, 385-391.	2.0	5
49	Acetate-free biofiltration to remove fibroblast growth factor 23 in hemodialysis patients: a pilot study. Journal of Nephrology, 2018, 31, 429-433.	2.0	5
50	Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist's Opinion. Journal of Clinical Medicine, 2020, 9, 1261.	2.4	5
51	Proteinuric effect of transcranial magnetic stimulation in healthy subjects and diabetic patients with Stage 3-4 CKD. Nephrology Dialysis Transplantation, 2014, 29, 573-579.	0.7	4
52	Stress-induced hashitoxicosis: case report and relative HLA serotype and genotype. Revista Da Associação Médica Brasileira, 2019, 65, 830-833.	0.7	4
53	<p>Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease</p> . Therapeutics and Clinical Risk Management, 2020, Volume 16, 871-880.	2.0	4
54	Gender differences in new hypoglycemic drug effects on renal outcomes: a systematic review. Expert Review of Clinical Pharmacology, 2022, 15, 323-339.	3.1	4

VALERIA CERNARO

VALERIA CERNARO

#	Article	IF	CITATIONS
55	Wernicke–Korsakoff Syndrome in Endâ€&tage Renal Disease: A Case Report. Therapeutic Apheresis and Dialysis, 2018, 22, 676-679.	0.9	3
56	Commonly used immunosuppressive drugs for kidney diseases and pregnancy: focus on open questions. Expert Review of Clinical Pharmacology, 2021, 14, 1-3.	3.1	3
57	Unexpected hypercalcemia in a diabetic patient with kidney disease. World Journal of Nephrology, 2015, 4, 438.	2.0	3
58	Correlation between Hyperkalemia and the Duration of Several Hospitalizations in Patients with Chronic Kidney Disease. Journal of Clinical Medicine, 2022, 11, 244.	2.4	3
59	Modifications in relaxin's serum levels during acetate-free biofiltration (AFB): only a new biomarker?. Italian Journal of Anatomy and Embryology, 2013, 118, 98-9.	0.1	3
60	Opposite actions of urotensin II and relaxinâ€⊋ on cellular expression of fibronectin in renal fibrosis: A preliminary experimental study. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 1069-1071.	1.9	2
61	Indole-3-acetic acid correlates with monocyte-to-high-density lipoprotein (HDL) ratio (MHR) in chronic kidney disease patients. International Urology and Nephrology, 2022, 54, 2355-2364.	1.4	2
62	Semaphorin <scp>3A</scp> serum levels are influenced by haemodialysis: What clinical significance?. Nephrology, 2015, 20, 236-242.	1.6	1
63	Research update for articles published in EJCI in 2009. European Journal of Clinical Investigation, 2011, 41, 1149-1163.	3.4	0
64	MP555SALT WATER DISEQUILIBRIUM AND FLUID OVERLOAD IN HEMODYALYSES PATIENTS: A CENTRAL ROLE OF CORIN. Nephrology Dialysis Transplantation, 2016, 31, i525-i525.	0.7	0
65	MP463FGF23 KINETICS AND REMOVAL ON HAEMODIAFILTRATION. Nephrology Dialysis Transplantation, 2016, 31, i495-i496.	0.7	0
66	Apelin and Copeptin as Biomarkers of Kidney Disease. , 2016, , 535-556.		0
67	Maternal peripheral blood CD34+ cells for prediction of fetal kidney malformations: results from a case-control analysis. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 1679-1682.	1.5	0
68	MO466A NOVEL PREDICTION MARKER OF 10-YEAR RISK AND LIFETIME RISK OF RECURRENT CARDIOVASCULAR EVENTS IN PATIENTS WITH CKD AND DIABETES MELLITUS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
69	Overview of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker in Nephrology. , 2015, , 1-24.		0
70	Apelin and Copeptin as Biomarkers of Kidney Disease. , 2015, , 1-22.		0
71	Overview of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker in Nephrology. , 2016, , 205-227.		0
72	MO217: Proteinuria/BMI Ratio in Primary Membranous Nephropathy as a Possible Predictive Factor of Therapeutic Efficacy. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0